Clinical Trial Finder

Inclusion Criteria:

• - Aged at least 18 years of age; male or female.

A patient who is 70 years of age or older may be considered for enrollment after review of patient clinical and laboratory data by the Protocol Medical Monitor.

• - Histologically confirmed diagnosis of GBM.

• - Contrast enhancing disease on MRI within 21 days prior to screening.

• - Karnofsky score (KPS) of ≥ 60 at Screening.

• - No prior RT, chemotherapy (including Gliadel wafer), immunotherapy or therapy with a biologic agent, or hormonal therapy.

Glucocorticoid therapy is allowed.

• - Within 2 weeks of baseline visit, hematologic and renal functions as specified: Absolute neutrophil count ≥ 1500/mm3, platelets ≥ 100,000/mm3, Hgb ≥ 9.0g/dL, creatinine ≤ 1.7mg/dl, total bilirubin ≤ 1.5mg/dL, blood urea nitrogen (BUN) within 2 times the upper limit of normal, transaminases ≤ 4 times above the upper limits of the institutional norm.

• - Sexually active patients must use an acceptable method of contraception while receiving doses of study medication.

• - Females of childbearing potential must have a negative serum or urine pregnancy test at screening and have additional pregnancy tests during study.

Exclusion Criteria:

• - Patient who cannot undergo MRI.

• - Pregnant or lactating.

• - Serious concurrent infection or medical illness that would jeopardize the ability of the patient to receive study treatment with reasonable safety.

• - Patient receiving concurrent chemotherapeutics or investigational agents within 30 days of baseline assessments, including gliadel wafers or gliasite application.

The overall objectives of this Phase 1/2 clinical study in newly diagnosed GBM patients was to evaluate the safety and tolerability, efficacy, PK profile, PFS/time to disease progression, QoL, and overall survival in adults when TSC is added to the standard of care regimen of radiation therapy and temozolomide. All patients received TSC in this study. The primary objective of the Phase 1 portion of the study was to evaluate the safety (DLT rate) and to define the dosing regimen of TSC for the larger Phase 2 study. The primary clinical endpoint was overall survival at 24 months and patients will be followed for up to 3 years.

Arms

Experimental: TSC 0.25 mg/kg for 9 or 18 doses

This was an open-label, sequential-cohort, dose-escalation study in two phases. Phase 1 was a safety run-in evaluating Trans Sodium Crocetinate (TSC) in 3 subjects who received 3 doses per week for 3 weeks (9 doses in total). Phase 2 engaged 56 subjects who received 3 doses per week for 6 weeks (18 doses in total). TSC was consistently dosed at 0.25mg/kg in both phases.

Interventions

Drug: - Trans Sodium Crocetinate (TSC)

TSC administered intravenously as a bolus injection prior to radiation therapy sessions during 6 weeks of radiotherapy.